A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an anti-Folate Receptor alpha Antibody Drug Conjugate (ADC), in Patients with Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal | Froedtert & the Medical College of Wisconsin

Protocol No

SUTRO-STRO-002-GM1

Principal Investigator

Denise Uyar

Phase

Summary

We want to find out more about the side effects (problems and symptoms) of a new drug for STRO-002 and what doses of STRO-002 are safe for people to take.

Description

Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate in Ovarian & Endometrial Cancers

Participating Institutions

Froedtert Hospital

Status

OPEN TO ACCRUAL

ClinicalTrials.gov

go to website

A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an anti-Folate Receptor alpha Antibody Drug Conjugate (ADC), in Patients with Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers